 |
|
1918 flu antibodies resurrected from elderly survivors
August 18, 2008Ninety years after the sweeping destruction of the 1918 flu pandemic, researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt have recovered antibodies to the virus - from elderly survivors of the original outbreak.
In addition to revealing the surprisingly long-lasting immunity to such viruses, these antibodies could be effective treatments to have on hand if another virus similar to the 1918 flu breaks out in the future.
The study, led by James Crowe Jr., M.D., professor of Pediatrics and director of the Vanderbilt Program in Vaccine Sciences, Christopher Basler, Ph.D., at the Mount Sinai School of Medicine, and Eric Altschuler, M.D., Ph.D., at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School, is published online in the journal Nature.
The influenza pandemic of 1918 killed nearly 50 million people worldwide, many of whom were young, healthy adults. With fears of another looming flu pandemic stoked by the emergence of "bird flu" in Asia, researchers have wanted to study the 1918 virus and the immune response to it.
In 2005, researchers from Mount Sinai and the Armed Forces Institute of Pathology in Washington, D.C., resurrected the 1918 virus from the bodies of people killed in the outbreak. The bodies, and the virus, had been preserved in the permanently frozen soil of Alaska.
When the investigators approached Crowe, whose lab had developed methods of making antibodies, to try to make antibodies to the 1918 flu, he was skeptical, but agreed to try.
The researchers collected blood samples from 32 survivors age 91-101 years and found that all reacted to the 1918 virus, suggesting that they still possessed antibodies to the virus.
Crowe's team was then able to isolate exceedingly rare B cells - the immune cells that produce antibodies - from eight of those samples and grow them in culture. Seven of those samples produced antibodies to a 1918 virus protein, suggesting that their immune systems were waiting on standby for a long-awaited second outbreak.
"The B cells have been waiting for at least 60 years - if not 90 years - for that flu to come around again," Crowe said. "That's amazing-because it's the longest memory anyone's ever demonstrated."
Crowe's team then fused cells showing the highest levels of activity against the virus with "immortal" cells to create a cell line that secretes monoclonal (or identical) antibodies to the 1918 flu. The antibodies reacted strongly to the 1918 virus and cross-reacted with proteins from the related 1930 swine flu but not to more modern flu strains.
To test if these antibodies still work against 1918 flu in a living animal, Crowe's collaborators at the Centers for Disease Control and Prevention infected mice with the 1918 flu and then administered the antibodies at varying doses. Mice receiving the lowest dose of 1918 antibody - and those receiving a non-reactive "control" antibody - died. All mice given the highest doses of 1918 antibodies survived.
Although aging typically causes immunity to weaken, "these are some of the most potent antibodies ever isolated against a virus," Crowe said. "They're the best antibodies I've ever seen."
The findings suggest that B cells responding to a viral infection - and the antibody-based immunity that results - may last a lifetime, even nine or more decades after exposure.
These antibodies could be used as potential treatments for future outbreaks of flu strains similar to the 1918 virus. And the technology could be used to develop antibodies against other viruses, like HIV.
Most importantly, said Crowe, "the lessons we are learning about the 1918 flu tell us a lot about what may happen during a future pandemic."
Vanderbilt University Medical Center
The influenza pandemic of 1918 killed nearly 50 million people worldwide, many of whom were young, healthy adults. With fears of another looming flu pandemic stoked by the emergence of "bird flu" in Asia, researchers have wanted to study the 1918 virus and the immune response to it.
In 2005, researchers from Mount Sinai and the Armed Forces Institute of Pathology in Washington, D.C., resurrected the 1918 virus from the bodies of people killed in the outbreak. The bodies, and the virus, had been preserved in the permanently frozen soil of Alaska.
When the investigators approached Crowe, whose lab had developed methods of making antibodies, to try to make antibodies to the 1918 flu, he was skeptical, but agreed to try.
The researchers collected blood samples from 32 survivors age 91-101 years and found that all reacted to the 1918 virus, suggesting that they still possessed antibodies to the virus.
Crowe's team was then able to isolate exceedingly rare B cells - the immune cells that produce antibodies - from eight of those samples and grow them in culture. Seven of those samples produced antibodies to a 1918 virus protein, suggesting that their immune systems were waiting on standby for a long-awaited second outbreak.
"The B cells have been waiting for at least 60 years - if not 90 years - for that flu to come around again," Crowe said. "That's amazing-because it's the longest memory anyone's ever demonstrated."
Crowe's team then fused cells showing the highest levels of activity against the virus with "immortal" cells to create a cell line that secretes monoclonal (or identical) antibodies to the 1918 flu. The antibodies reacted strongly to the 1918 virus and cross-reacted with proteins from the related 1930 swine flu but not to more modern flu strains.
To test if these antibodies still work against 1918 flu in a living animal, Crowe's collaborators at the Centers for Disease Control and Prevention infected mice with the 1918 flu and then administered the antibodies at varying doses. Mice receiving the lowest dose of 1918 antibody - and those receiving a non-reactive "control" antibody - died. All mice given the highest doses of 1918 antibodies survived.
Although aging typically causes immunity to weaken, "these are some of the most potent antibodies ever isolated against a virus," Crowe said. "They're the best antibodies I've ever seen."
The findings suggest that B cells responding to a viral infection - and the antibody-based immunity that results - may last a lifetime, even nine or more decades after exposure.
These antibodies could be used as potential treatments for future outbreaks of flu strains similar to the 1918 virus. And the technology could be used to develop antibodies against other viruses, like HIV.
Most importantly, said Crowe, "the lessons we are learning about the 1918 flu tell us a lot about what may happen during a future pandemic."
Vanderbilt University Medical Center
Antibodies Current Events and Antibodies News RSSAdult stem cell breakthrough
The first tissue-engineered trachea (windpipe), utilising the patient's own stem cells, has been successfully transplanted into a young woman with a failing airway. The bioengineered trachea immediately provided the patient with a normally functioning airway, thereby saving her life.
Researchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.
First trial of gene therapy for advanced heart failure shows promising results
Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity.
T cell-based HIV vaccine candidate demonstrates positive results
The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.
Mayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer.
Penn Scientists Show How Body Determines Optimal Amount of Germ-Fighting B Cells
Researchers at the University of Pennsylvania School of Medicine can now explain how the body determines whether there are enough mature B-cells in the blood stream at any one time. These are the cells that produce antibodies against germs to fight infections.
New research finds markers for esophageal cancer before it develops
Rhode Island Hospital researchers have identified genetic proteins, also known as biomarkers, capable of distinguishing changes at the microscopic level that can signal a precancerous condition in the esophagus.
How HIV vaccine might have increased odds of infection
In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection.
Drinking milk to ease milk allergy?
Giving children with milk allergies increasingly higher doses of milk over time may ease, and even help them completely overcome, their allergic reactions, according to the results of a study led by the Johns Hopkins Children's Center and conducted jointly with Duke University.
A reversal of thinking: How women with lupus can increase chance for healthy pregnancies
In the not so distant past, women with systemic lupus erythematosus (SLE), an autoimmune disease, were advised not to have children, and if they became pregnant, to have therapeutic abortions to prevent severe flares of their lupus.
More Antibodies Current Events and Antibodies News Articles
 | Antibodies: A Laboratory Manual by Ed Harlow, David Lane Introduction to immunochemistry for molecular biologists and other nonspecialists.... |
 | Recombinant Antibodies for Cancer Therapy: Reviews and Protocols (Methods in Molecular Biology) (Methods in Molecular Biology) In Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Martin Welschoff and Jürgen Krauss present a collection of carefully selected protocols for the design, construction, and characterization of novel anticancer therapeutics based on recombinant antibody technology. These readily reproducible methods include coverage of hybridoma-derived recombinant antibodies, recombinant... |
 | Monoclonal Antibodies, Third Edition: Principles and Practice by James W. Goding Monoclonal Antibodies now have applications in virtually all areas of biology and medicine, and much of the world's biotechnology industry has its foundations in the exploitation of this technology.The Third Edition of this well established book meets the needs of both newcomers to the area and experienced researchers, by providing an integrated treatment of both the production and application of... |
 | Handbook of Therapeutic Antibodies 3-Volume Set In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently... |
 | Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology) Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion... |
 | Making and Using Antibodies: A Practical Handbook Antibodies are an indispensable tool in the study of biology and medicine. Making and Using Antibodies: A Practical Handbook presents techniques in a single, comprehensive source for the production and use of antibodies. It enables researchers to immediately access lab-tested, proven protocols. Written and edited by an elite team of scientists, who have developed and refined many of the... |
 | Using Antibodies : A Laboratory Manual : Portable Protocol NO. I by Ed Harlow, David Lane A guide to the use of immunoglobulin reagents in the laboratory. It provides background, context and step-by-step instructions for techniques that range from choosing the right antibody and handling it correctly, to the proper methods for characterizing antigens in cells and solutions. Also included are chapters on tagging proteins and epitope mapping. Rather than presenting an array of solutions... |
 | Therapeutic Antibodies (Handbook of Experimental Pharmacology) (Handbook of Experimental Pharmacology) Antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions and are becoming the molecules of choice for further combination therapies and cell engineering. Current developments and clinical successes are summarized by experts in the drug development field. A must read for immunologists, clinical scientists and novel drug... |
 | Antibody Engineering: Methods and Protocols (Methods in Molecular Biology) (Methods in Molecular Biology) A core collection of diverse cutting-edge techniques for the generation, expression, optimization, and characterization of recombinant antibodies. Readily reproducible protocols for lead generation range from the cloning of human immunoglobulin genes to the selection and generation of human recombinant antibodies by humanization approaches, molecular display technologies and transgenic animals.... |
 | Manual of Diagnostic Antibodies for Immunohistology by Anthony S-Y. Leong, Kumarasen Cooper, F. Joel W-M. Leong The rapid acceptance of immunohistochemistry as an important and even indispensable adjunct to morphological examination and diagnosis requires the modern anatomical pathology laboratory to be conversant with, and proficient in, immunostaining procedures, as well as methods of tissue processing and antigen retrieval and the underlying characteristics of the increasing number of antibodies and... |
| © 2008 BrightSurf.com |